Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.35 |
| ▸ | VCP | P55072 | 6/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23169336 | 0.89 | EZH2 (0.55) | EZH2GRIN2BVCPMERTKHCAR3 | |
| SCHEMBL23169315 | 0.89 | EZH2 (0.50) | EZH2GRIN2BACACBCCNT1HRH4 | |
| SCHEMBL23169582 | 0.89 | EZH2 (0.54) | EZH2GRIN2BVCPACACBCCNT1 | |
| SCHEMBL23169460 | 0.89 | EZH2 (0.61) | EZH2GRIN2BACACBCCNT1MERTK | |
| SCHEMBL23169555 | 0.87 | EZH2 (0.54) | EZH2HCAR3 | |
| SCHEMBL23169617 | 0.86 | EZH2 (0.66) | EZH2GRIN2BVCPACACBCCNT1 | |
| SCHEMBL23169671 | 0.86 | EZH2 (0.50) | EZH2CCNT1HRH4MERTKCCNA2 | |
| SCHEMBL24701362 | 0.86 | EZH2 (0.50) | EZH2CCNT1HRH4MERTKCCNA2 | |
| SCHEMBL23169570 | 0.86 | EZH2 (0.51) | EZH2VCPACACBCCNT1MERTK | |
| SCHEMBL23169326 | 0.85 | EZH2 (0.49) | EZH2CCNT1HRH4HRH3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2021057853-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | EZH2 1/4885GRIN2B 354/4885VCP 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.